Geode Capital Management
ONCT

Geode Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Geode Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,879
Closed -$34.2K – 4599
2024
Q3 		$34.2K Hold
25,879
– – ﹤0.01% 4334
2024
Q2 		$197K Buy
25,879
+1,800
+7% +$15.5K ﹤0.01% 3915
2024
Q1 		$217K Buy
+24,079
New +$212K ﹤0.01% 3917
2023
Q4 		– Sell
-23,797
Closed -$144K – 4712
2023
Q3 		$144K Buy
23,797
+3,018
+15% +$21.3K ﹤0.01% 4114
2023
Q2 		$143K Hold
20,779
– – ﹤0.01% 4194
2023
Q1 		$326K Hold
20,779
– – ﹤0.01% 3821
2022
Q4 		$415K Buy
20,779
+299
+1% +$5.95K ﹤0.01% 3750
2022
Q3 		$365K Hold
20,480
– – ﹤0.01% 3897
2022
Q2 		$454K Sell
20,480
-20,351
-50% -$454K ﹤0.01% 3829
2022
Q1 		$1.14M Buy
40,831
+2,390
+6% +$87K ﹤0.01% 3556
2021
Q4 		$1.75M Buy
38,441
+319
+0.8% +$21.5K ﹤0.01% 3435
2021
Q3 		$3.18M Buy
38,122
+1,152
+3% +$95.3K ﹤0.01% 3158
2021
Q2 		$3.51M Buy
36,970
+18,774
+103% +$2.23M ﹤0.01% 3101
2021
Q1 		$3.03M Buy
18,196
+11,022
+154% +$1.46M ﹤0.01% 3043
2020
Q4 		$703K Buy
7,174
+6,215
+648% +$393K ﹤0.01% 3481
2020
Q3 		$32K Hold
959
– – ﹤0.01% 4082
2020
Q2 		$54K Buy
959
+70
+8% +$3.95K ﹤0.01% 3965
2020
Q1 		$52K Buy
889
+39
+5% +$2.91K ﹤0.01% 3916
2019
Q4 		$67K Buy
850
+143
+20% +$14.8K ﹤0.01% 4043
2019
Q3 		$70K Sell
707
-302
-30% -$30.9K ﹤0.01% 4014
2019
Q2 		$134K Sell
1,009
-664
-40% -$103K ﹤0.01% 3886
2019
Q1 		$280K Buy
1,673
+63
+4% +$9.4K ﹤0.01% 3638
2018
Q4 		$175K Sell
1,610
-224
-12% -$44.8K ﹤0.01% 3711
2018
Q3 		$403K Buy
1,834
+1,361
+288% +$3.27M ﹤0.01% 3544
2018
Q2 		$1.01M Buy
473
+143
+43% +$363K ﹤0.01% 3183
2018
Q1 		$819K Buy
330
+43
+15% +$95.8K ﹤0.01% 3213
2017
Q4 		$510K Hold
287
– – ﹤0.01% 3354
2017
Q3 		$329K Buy
287
+19
+7% +$17.1K ﹤0.01% 3496
2017
Q2 		$198K Sell
268
-14
-5% -$8.59K ﹤0.01% 3689
2017
Q1 		$192K Buy
282
+2
+0.7% +$1.47K ﹤0.01% 3667
2016
Q4 		$207K Buy
280
+1
+0.4% +$1.07K ﹤0.01% 3612
2016
Q3 		$306K Buy
279
+29
+12% +$25.3K ﹤0.01% 3454
2016
Q2 		$192K Hold
250
– – ﹤0.01% 3608
2016
Q1 		$175 Sell
250
-1
-0.4% -$867 ﹤0.01% 3672
2015
Q4 		$245K Buy
251
+1
+0.4% +$1.32K ﹤0.01% 3601
2015
Q3 		$266K Buy
250
+121
+94% +$177K ﹤0.01% 3543
2015
Q2 		$265K Hold
129
– – ﹤0.01% 3487
2015
Q1 		$121K Hold
129
– – ﹤0.01% 3714
2014
Q4 		$131K Buy
129
+39
+43% +$34.8K ﹤0.01% 3723
2014
Q3 		$92K Buy
90
+10
+13% +$14.7K ﹤0.01% 3764
2014
Q2 		$153K Sell
80
-9
-10% -$17.8K ﹤0.01% 3596
2014
Q1 		$191K Buy
89
+3
+3% +$7.47K ﹤0.01% 3501
2013
Q4 		$198K Buy
86
+2
+2% +$4.58K ﹤0.01% 3439
2013
Q3 		$237K Buy
84
+1
+1% +$4.98K ﹤0.01% 3251
2013
Q2 		$763K Buy
+83
New +$640K ﹤0.01% 2626

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Geode Capital Management's ONCT Position: Q4 2024 in Review

Geode Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 25,879 shares — an estimated $34.2K sold.

Geode Capital Management first reported a position in ONCT in Q2 2013 and held it in 45 quarters. The position peaked at $3.51M in Q2 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Geode Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Geode Capital Management sold 25,879 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $34.2K.
  • Geode Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 45 quarters.
  • Geode Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.51M in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Geode Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.